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Background: Since ovarian cancer is associated with high frequency of p53 mutation, the availability of p53
reactivation and induction of massive apoptosis (PRIMA-1) offers a possible new therapeutic strategy for
overcoming this devastating disease. Although Akt activation is believed to be a determinant in chemoresistance in
ovarian cancer, whether Akt plays a role in regulating the effectiveness of PRIMA-1 in sensitizing chemoresistant
ovarian cancer cells with p53 mutation to cisplatin (CDDP), remains to be determined.
Methods: In the present studies, we examined the influence of Akt down-regulation following dominant-negative
(DN-Akt) expression on the ability of PRIMA-1 (0–10 μM) to facilitate CDDP (0–10 μM)-induced apoptosis in
p53-mutated chemoresistant ovarian cancer cells (A2780cp).
Results: Apoptosis rate was significantly higher at the combined treatment of low PRIMA-1 concentrations
(0.156 - 0.938 μM) plus CDDP (10 μM) in the DN-Akt groups than control (p<0.001). Apoptosis in cells treated with
PRIMA-1 (0.156 μM) and CDDP treatment (10 μM) was significantly suppressed by p53-siRNA. PRIMA-1 increased
phospho-p53 (Ser15) content in Akt down-regulated cells treated with CDDP.
Conclusions: These results demonstrate that PRIMA-1 can sensitize chemoresistant ovarian cancer cells with p53
mutation to CDDP when Akt is down-regulated, and the action of PRIMA-1 is associated with p53 activation. Our
findings raise the possibility that PRIMA-1 may be useful candidate for adjuvant therapy with CDDP in
chemoresistant ovarian cancer with p53 mutation when Akt is down-regulated.
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Ovarian cancer is the most lethal gynecological malig-
nancies. Currently, the preferred treatment for ovarian
cancer is combination chemotherapy, usually with a
platinum based drug (e.g. CDDP or carboplatin), together
with surgical debulking. The effectiveness of many of
the chemotherapeutic agents in human cancer is
highly dependent on the ability of the cancer cells to
undergo drug-induced apoptosis. The development of* Correspondence: btsang@ohri.ca
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treatment in human ovarian cancer.
The tumor suppressor p53 inhibits tumor growth
primarily by induction of apoptosis through mechanisms
which are transcription-dependent [1,2] and –independent
[3-5]. p53 binds to a specific DNA sequence and transacti-
vates target genes leading to cell cycle arrest and/or apop-
tosis. p53 dependent apoptosis is an important determining
factor on the efficacy of chemotherapy, as tumors with p53
mutation are often more resistant to chemotherapeutic
agents compared to those harboring wild-type p53 (wt-p53)
[6,7]. Mutations in p53 occur in nearly half of human
ovarian tumors. A majority being missense mutations in
the DNA-binding core domain, thus resulting in deficient
DNA binding [8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factors and cytokines in a phosphatidylinositol-3-OH-kinase
(PI3K)-dependent manner [9,10]. Akt is implicated in cell
proliferation and survival and is a key determinant of
CDDP resistance in ovarian cancer cells which are
p53 dependent [5]. We have previously demonstrated that
Xiap, Akt and p53 interact in the regulation of chemosensi-
tivity in ovarian cancer cells [2]. The PI3K-Akt pathway is
over-expressed or activated in chemoresistant ovarian can-
cer cells and Akt down-regulation sensitizes chemoresistant
wt-p53 cells to CDDP-induced apoptosis [2,11]. The latter
response, however, is not evident in mutant-p53 cells unless
reconstituted with wt-p53.
PRIMA-1, a low molecular weight compound, is more
effective in inducing apoptosis in mutant-p53 cells than
the wt-p53 cells and has noticeable anti-tumor activity
in vitro and in vivo [12]. The sensitivity of PRIMA-1 was
related to mutant p53 expression levels [13]. It is capable
to induce apoptosis in human tumor cells through
restoring the transcriptional function to mutant-p53
[14]. PRIMA-1 and the structural analog PRIMA-1
MET, also named APR-246, reactivate mutant p53
through covalent binding to the core domain and induce
apoptosis in tumor cells. Its anti-tumor effect does not
appear to be due to general toxicity [14]. Although
PRIMA-1 is capable of restoring chemosensitivity in
mutant-p53 cells, whether it acts synergistically with
CDDP to inhibit proliferation of mutant-p53 ovarian
cancer cells is unclear. Moreover, whether Akt plays a role
in regulating the effectiveness of PRIMA-1 in sensitizing
chemoresistant mutant-p53 ovarian cancer cells to CDDP,
remains to be determined.
In the present studies, we have investigated the role of
Akt in this regards and demonstrated that Akt down-
regulation induce significant apoptosis in combination
treatment of PRIMA-1 and CDDP in chemoresistant
ovarian cancer cells carrying p53 mutation.
Materials and methods
Reagents
Cells were cultured at 37°C with 5% CO2 in DMEM
(Dulbecco’s modified Eagle’s medium)/F12 (Invitrogen Inc.,
Burlington, ON, Canada). Medium was supplemented with
10% fetal bovine serum (FBS), streptomycin (100 μg/mL),
penicillin (100U/mL), and fungizone (0.625 μg/mL).
PRIMA-1 was purchased from Calbiochem, Inc. (San
Diego, CA, USA). Cis-diaminedichloroplatinum (CDDP)
and Hoechst 33258 were supplied by Sigma (Oakville, ON,
Canada). Adenoviral dominant-negative Akt (DN-Akt) was
a gemerous gift from Dr. Kenneth Walsh (Cardiovascular
Research, St. Elizabeth’s Medical Centre, Boston, MA).
Adenoviral LacZ was synthesized at the Neuroscience
Research Institute, University of Ottawa (Ottawa, ON,
Canada). Small inhibitory RNA (siRNA) to p53, scrambledsequence siRNA (control) and Mouse monoclonal
anti-phospho-p53 (Ser15) were from Cell Signaling
Technology Inc. (Beverly, MA, USA). Mouse monoclonal
anti-glyceraldehyde phosphate dehydrogenase (GAPDH)
was from Abcam (Cambridge, MA, USA).
Cell culture, adenoviral infection and treatment of PRIMA-1
and CDDP
Chemoresistant ovarian cancer cells (A2780cp: p53-mutant
cell line) were cultured and treated as reported previously
[2]. Cells were plated into 60 mm dishes in DMEM/F12
and infected with adenoviral DN-Akt construct (MOI = 40)
for 48 h. Infection with adenoviral LacZ served as control
and was used to normalize the total dose of adenovirus be
same in each treatment group. Cells were treated with
PRIMA-1 (0–10 μM) for 8 hours, and then harvested at
24 hours following CDDP treatment (0–10 μM). All CDDP
treatment was performed in serum-free media.
Assessment of apoptosis
At the end of treatment period, cells attached to the growth
surface were harvested by trypsin treatment. Floating and
attached cells were then pooled and centrifuged, and the
pellet were resuspended in phosphate buffered formalin
(10%) containing Hoechst 33258 (12.5 ng/ml). Cells were
spotted onto slides and changes in nuclear morphology
were observed using a Zeiss fluorescence microscope
(magnification 400X), as previously reported [15,16]. A
minimum of 200 cells with typical apoptotic nuclear
morphology (nuclear shrinkage, condensation and frag-
mentation) were counted in each treatment group from
randomly selected fields and expressed as the percentage
of total cells [3,17]. The counter was “blinded” to sample
identity to avoid experimental bias.
Transfection with p53-siRNA
After 12–18 hours of plating, cells were infected with
adenoviral DN-Akt (MOI = 40; 48 h). To determine if the
action of PRIMA-1 was mediated by p53, the cells were,
transfected with p53-specific or control siRNA (50 nM)
24 h after the infection and then treated with PRIMA-1
(0.156 μM) for 8 h. The cells were harvested at 24 h after
CDDP treatment (10 μM). p53 down-regulation was
confirmed by Western blot analysis [3,4,15,17].
Protein extraction and Western blotting
Protein extraction and Western blotting were performed as
described previously [2]. Membranes were incubated over-
night at 4°C with primary anti-p53 (1:1000), anti-GAPDH
(1:2,000), and subsequently detected with horseradish
peroxidase-conjugated goat IgG raised against the
corresponding species. Peroxidase activity was visua-
lized with an enhanced chemiluminescence (ECL) kit
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Figure 1 The effect of different concentration of PRIMA-1 on
CDDP-induced apoptosis in chemoresistant p53-mutant ovarian
cancer cells with/without Akt down-regulation. Apoptosis rate
was evaluated with difference concentration of PRIMA-1 (0–10 μM)
plus CDDP (0 or 10 μM) using adenoviral DN-Akt (_____) or LacZ
(. . .. . ..; as control). *** P<0.001; PRIMA-1+CDDP & DN-Akt vs. PRIMA-1
& DN-Akt; +++ P<0.001, ++ P<0.01 ; PRIMA-1+CDDP & DN-Akt vs.
PRIMA-1+CDDP & CTL; ### P<0.001, ## P<0.01 ; PRIMA-1+CDDP &
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Figure 2 The influence of different CDDP concentration on the
PRIMA-induced apoptosis following Akt down-regulation.
Apoptosis rate was analyzed with different concentration of CDDP
(0–10 μM) plus PRIMA-1 (0 or 0.625 μM) which was strong enough
to induce apoptosis in the combined treatment of CDDP in the
absence (. . .. . ..) and presence (_____) of DN-Akt. ### P<0.001, ##
P<0.01; PRIMA-1+CDDP & DN-Akt vs. PRIMA-1 & CTL. Results are
expressed as mean ± SEM of three independent experiments.
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software, version 4.02, from Scion Corporation (Frederick,
MD, USA).
Statistical analyses
All results are expressed as mean ±SEM of at least three
independent experiments. Data were analyzed by two-way
ANOVA and the differences between multiple experimental
groups determined by Bonferoni post-hoc tests (PRISM
software version 3.0, GrahPad, San Diego, CA). Statistical
significance was inferred at P<0.05.
Results
PRIMA-1 together with Akt down-regulation sensitizes
chemoresistant ovarian cancer cells with mutant-p53 to
CDDP in vitro
Tumor suppressive p53 is required for CDDP sensisitivity
[1,2]. P53 mutation is often associated with chemoresistance
in ovarian cancer [18]. We have previously demonstrated
that CDDP is unable to induce apoptosis in p53-mutated
ovarian cancer cells unless reconstituted with wt-p53
and Akt function down-regulated. To investigate whether
PRIMA-1 increases CDDP sensitivity in mutant-p53
chemoresistant ovarian cancer cells and if its action is
depending on Akt down-regulation, A2780cp cells were
infected with adenoviral DN-Akt (MOI = 40; LacZ as
control) for 48 h, treated with PRIMA-1 (0–10 μM; 8 h),
and then harvested after CDDP treatment (0–10 μM;
24 h). As shown in Figure 1, in the presence of CDDP
and DN-Akt, apoptosis rate was significantly higher in
PRIMA-1 (0.156 - 10 μM; p<0.01) than LacZ control.
While PRIMA-1 alone was ineffective in the LacZ control
groups, it significantly induced apoptosis in the DN-Akt
groups in a concentration-dependent manner (0.938 -
10 μM; p<0.01). Apoptosis was significantly induced in the
low concentration of PRIMA-1 (0.156 - 0.938 μM: p<0.01)
plus CDDP groups compared to PRIMA-1 alone group
with DN-Akt (p<0.001), this response was not evident at
higher concentrations (1.25 – 10 μM; p > 0.05). There was
no difference in apoptosis rate between PRIMA-1 alone
groups and PRIMA-1 plus CDDP groups without DN-Akt.
To further examine the role of PRIMA-1 in the regulation
of CDDP sensitivity, the above experiment carried out with
different concentration of CDDP (0–10 μM) and PRIMA-1
(0.625 μM) which was strong enough to induce apoptosis
in the combined treatment of CDDP in the absence and
presence of DN-Akt. While CDDP was unable to induce
apoptosis with LacZ control, PRIMA-1 and/or DN-Akt
groups, it induces cell death in the presence of both
PRIMA-1 and DN-Akt group in a concentration dependent
manner (Figure 2). Apoptosis was significantly higher in the
DN-Akt groups in a CDDP concentration (5–10 μM) with
maximal response observable at 0.625 μM PRIMA-1 and
10 μM CDDP.p53 - specific action of PRIMA-1
We next elucidated whether p53 is involved in the
synergistic effect of PRIMA-1 and CDDP with DN-Akt
(Figure 3). A2780cp cells were infected with adenovirus
containing DN-Akt (MOI = 40; 48 h), transfected with
p53 or control siRNA, treated with least concentration of
PRIMA-1 (0–0.156 μM; able to induce significant
apoptosis in above experiments; 8 h), and harvested at 24 h
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Figure 3 PRIMA-1-facilitated CDDP-induced apoptosis in Akt
down-regulated chemoresistant p53-mutant ovarian cancer
cells is mediated by p53. Akt function was down-regulated by
adenoviral DN-Akt infection (MOI = 40). Apoptotic rate was
evaluated to determione whether p53 is involved in the synergistic
effect of PRIMA-1 and CDDP following transfection with p53 or
control siRNA. *** p<0.001 vs CDDP & DN-Akt; Results are expressed
as mean ± SEM of three independent experiments.
p-p53 (Ser15) 
LacZ (MOI = 40) 
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Figure 4 PRIMA-1 increases p-p53 content in chemoresistant
p53-mutant ovarian cancer cells treated with CDDP when Akt
was down-regulated. Changes in p-p53 (Ser15) content following
PRIMA-1 and/or CDDP treatment with/without Akt down-regulation
were assessed by Western blot. Results are normalized against GAPDH
and expressed as fold of control. * p<0.05 vs CDDP & DN-Akt; Values
are mean ± SEM of three independent experiments.
Kobayashi et al. Journal of Ovarian Research 2013, 6:7 Page 4 of 6
http://www.ovarianresearch.com/content/6/1/7in Figure 3, PRIMA-1 and CDDP were unable to sensitize
the cells neither in the presence of p53 nor control siRNA.
However, the combination groups of PRIMA-1 and CDDP
with DN-Akt dramatically induces apoptosis in the cells
transfected with control siRNA, a response which was
significantly suppressed in the group with p53-siRNA.
The action of PRIMA-1 is associated with p53 activation
in vitro
PRIMA-1 sensitizes the effect of CDDP when Akt function
is down-regulated in p53-mutant ovarian cancer cells.
Although our data suggests that p53 is required for this
effect, the mechanism involved is unclear. To determine
whether the action of PRIMA-1 is mediated through p53
phosphorylation and thus its activation, phospho-p53
(Ser15) content in A2780cp cell extracts from the above
experiments were determined by Western blot. As shown
in Figure 4, p53 phosphorylation was not evident in LacZ
group in the absence and presence of CDDP, although this
response was detected with PRIMA-1 and DN-Akt alone
and in the presence of CDDP. Down-regulation of Akt
markedly enhanced this response, activated p53 and
sensitized the cells in the induction of apoptosis by the
combined treatment with PRIMA-1 and CDDP. PRIMA-1
increased phospho-p53 (Ser15) content in Akt down-
regulated cells treated with CDDP, suggesting that the
action of PRIMA-1 in facilitating CDDP-induced apoptosisin p53 mutant chemoresistant ovarian cancer cells may in
part be mediated through increased p53 phosphorylation at
Ser15 (Figure 4).
Discussion
In the present study, we have shown that PRIMA-1 can
sensitize chemoresistant ovarian cancer cells with p53
mutation to CDDP when Akt function is down-regulated.
Our data also suggest that the action of PRIMA-1 is
associated with p53 phosphorylation and activation. The
mechanism by which PRIMA-1 sensitizes mutant p53 and
induces apoptosis has not been well elucidated. Whether
PRIMA-1 binds directly to mutant p53 or it acts through
indirect mechanisms remains an opened question. p53
binds to a specific DNA sequence and transactivates target
genes involved in the regulation of cell cycle arrest and
apoptosis. Tumor cells containing wt-p53 are usually
more chemosensitive than those bearing mutant p53. We
have previously shown that while CDDP up-regulates p53
in CDDP-sensitive wt-p53 cells (OV2008), but not its
resistant wt-p53 variant (C13*) in vitro, suggesting that
regulation of p53 content/function by CDDP may be an
important determinant of sensitivity [2].
PRIMA-1 synergizes with chemotherapeutic drugs to
induce tumor cell apoptosis [12,19-21]. PRIMA-1 restores
wild-type confirmation to mutant p53 by binding to the
core and induces apoptosis in human tumor cells.
Whereas wt-p53 is rapidly degraded by MDM2 in normal
cells, the mutant p53 protein fails to undergo degradation
in tumor cells and accumulates extensively [22]. Several
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the sequence-specific DNA-binding and to transactivate
some mutant p53 proteins in vitro and to induce apop-
tosis in vivo [12,23-25]. p53 activates many genes involved
in cell cycle arrest and apoptosis, mainly through its
transcription-dependent activity [26,27]. It is essential that
p53 reactivation in tumor cells trigger apoptosis rather
than cell arrest, as the therapeutic goal is to kill the tumor
cells. Heat shock protein 90 is a candidate target for p53
mutation reactivation by PRIMA-1 in breast cancer cells
[28]. Some data have indicated that treatment with
PRIMA-1 leads to upregulation of at least some of p53
target genes; for example, Bax and Noxa but not c-Jun-
NH2-kinase (JNK) signaling [29,30]. On the other hand,
Li et al. reported that JNK pathway plays an important
role on PRIMA-1-induced apoptosis [31]. Others have
shown that PRIMA-1 is capable of inducing apoptosis in a
transcription independent manner [32] or even mutant
p53-independent [33]. It has also been reported that
PRIMA-1 induces activation of caspase-2, caspase-3 and
caspase-9, consistent with induction of apoptosis via the
mitochondrial pathway [25]. Microarray analysis revealed
that PRIMA-1 induces a limited set of genes in a mutant
p53-dependent manner, followed by ER stress [34].
Akt activation promotes cell survival, suppresses
apoptotic death and confers resistance of ovarian cancer
cells to CDDP-induced apoptosis [2,11,35]. Over-expres-
sion/activation of the PI3K-Akt pathway is commonly
observed in ovarian cancer [36,37]. However, precisely how
Akt controls p53 activation is still unclear. Activation of
Akt promotes the entry of MDM2 into the nucleus and its
interaction with the tumor suppressor protein p53. Binding
of MDM2 to p53 inhibits the transcriptional activity of
p53 and targets it for proteasomal degradation [38]. We
previously demonstrated that activated Akt is an important
regulator of both X-linked inhibitor of apoptosis protein
(Xiap) and p53 levels after CDDP challenge and that
p53 mutational status is a determinant of Akt-mediated
chemoresistance [2,11]. Inhibition of Akt activity facilitated
the CDDP-induced mitochondrial release and nuclear
accumulation of apoptosis-inducing factor (AIF)-dependent,
CDDP-induced apoptosis [39]. Activation of Akt confers
resistance by blocking p53-mediated transactivation and
p53 phosphorylation [1]. In the present study, suppression
of Akt sensitized chemoresistant cells to CDDP in a p53-
dependent manner, suggesting a functional link between
Akt-mediated chemoresistance and p53.
Recent data demonstrated that p53 is essential for
CDDP-induced apoptosis in human ovarian cancer cells,
and that p53-mediated apoptosis is dependent on the
phosphorylation of several N-terminal residues, including
Ser15, Ser20 and Ser37 [40-42]. Our previous data
suggested that this is mediated, at least in part, through the
phosphorylation of p53 on Ser15 and Ser20 [1]. As Ser15phosphorylation affects p53 stability [43], phosphorylation
of p53 at serine15 by PRIMA-1 seems to be involved in
the reactivation of p53 transcriptional function. Mutation
of Ser15 to Ala significantly attenuates p53-mediated
apoptosis [42]. Our data show that down-regulation of
Akt sensitizes the cells to CDDP-induced apoptosis and
p-p53 at Ser15 is associated in the PRIMA-1-CDDP
interaction, suggesting that Ser15 phosphorylation is
needed for its function and apoptosis. This also suggests
that CDDP induces p53 phosphorylation on Ser15
residue, which absent in chemoresistant cells and is
required for CDDP-induced apoptosis. Akt efficiently
blocks this processes, thereby conferring resistance to
CDDP-induced apoptosis. In addition, while Akt modulates
other p53-dependent cellular events, including the down-
regulation of FLIP, our evidence suggests that effective
p53 phosphorylation and activation is essential for CDDP-
induced apoptosis. Thus, it will be of interest to study the
effects of chemotherapy on total and phospho-p53 in
human ovarian tumors. Moreover, since Akt attenuates
both processes, it is important to study the relationship
between activation/overexpression of Akt in ovarian
tumors and sensitivity to CDDP.
In summary, inhibition of Akt activity may represent a
novel therapeutic approach to the combined treatment
of PRIMA-1 and CDDP. Further examination of the role
and regulation of Akt in the PRIMA-1-CDDP interaction
in the ovarian tumour xenograft might provide novel
insights into a possible new therapy for chemoresistant
ovarian cancer.
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